Trial | First/Second Line | N | RR (%) | PFS (mo) | OS (mo) | Ref. |
Bevacizumab + paclitaxel | Second | 12 | 16.6 | 3.7 | n.g. | [25] |
Bevacizumab + carboplatin + paclitaxel | First | 53 | 17 | 6 | 12 | [26] |
Bevacizumab + carboplatin + paclitacel vs. placebo + carboplatin + paclitaxel | First | 214 | 25.5/16.4 | 5.6/4.2 | 12.3/8.6 | [9] |
Bevacizumab + temozolomide vs bevacizumab + nab-paclitaxel + carboplatin | First | 42/51 | 23.8/33.3 | 3.8/6.7 | 12.3/13.9 | [27] |
Bevacizumab + temozolomide | First | 62 | 16.1 | 4.2 | 9.6 | [18] |
Bevacizumab + nab-paclitaxel | First | 50 | 36 | 7.6 | 16.8 | [28] |
Bevacizumab + ipilimumab | First | 46 | 20 | 9 | 25.1 | [14] |
Bevacizumab + dacarbazine | First | 37 | 19 | 5.5 | 11.4 | [29] |